NEW BIOLOGICAL DRUGS IN THE TREATMENT OF ALLERGIC DISEASES. DOMESTIC EXPERIENCE IN THE USE OF DUPILUMAB IN ATOPIC DERMATITIS.

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In recent years, there has been a clear trend towards an increase in the number of patients with severe atopic dermatitis. In most cases, patients are dissatisfied with the previous therapy, which requires hospital treatment to relieve acute manifestations of atopic dermatitis and the selection of pharmacological agents aimed at achieving long-term control over the symptoms of the disease.

             The pathogenesis of atopic dermatitis is based on T2 type immune inflammation, which is confirmed by the secretion of the cytokines IL-4, IL-13, TSLP and IL-33. The introduction of biologics aimed at individual and specific components of T2 inflammation is a priority in the treatment of atopic dermatitis. One of these drugs is Dupilumab, which acts against the α subunit of the IL-4Rα receptor, which is common to the IL-4 / IL-13 receptors. The IL-4 / IL-13 / STAT6 signaling pathway, which plays a crucial role in T2 inflammation, is also inhibited.

            This article presents a clinical case showing the efficacy of using Dupilimab in a 7-year-old child suffering from atopic dermatitis.

Full Text

Restricted Access

About the authors

Vera A. Revyakina

The Federal Research Center for Nutrition, Вiotechnology and Food Safety

Author for correspondence.
Email: 5356797@mail.ru
ORCID iD: 0000-0002-1149-7927

Head of Allergy Department

Russian Federation, Moscow

Inna A. Larkova

The Federal Research Center for Nutrition, Вiotechnology and Food Safety

Email: inna_larkova@mail.ru
ORCID iD: 0000-0001-7640-0754

Senior researcher of Allergy Department, MD

Russian Federation, Moscow

E D Kuvshinova

Federal Research Centre of Nutrition and Biotechnology

Email: len.kuwshinowa@yandex.ru

старший научный сотрудник отделения аллергологии, кандидат медицинских наук

Moscow, 115445, Russian Federation

V A Mukhortykh

Federal Research Centre of Nutrition and Biotechnology

Email: valera-89@yandex.ru
ORCID iD: 0000-0001-8549-9493

младший научный сотрудник отделения аллергологии, кандидат медицинских наук

Moscow, 115445, Russian Federation

Kseniya Melnikova

ФГБУН "ФИЦ питания и биотехнологии"

Email: melnikova_ksenya85@bk.ru

Аспирант

References

  1. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases, J Clin Invest.2019; 130:1493-1503. doi: 10.1172/jci124611
  2. Ильина НИ, Курбачева ОМ. Моноклональные антитела в системе противоастматического лечения. Российский аллергологический журнал. 2018;15(3):5-15.
  3. Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy; 2020:75 (2):311-325. doi: 10.1111/all.13985
  4. Busse WW. Biological treatments for severe asthma. A major advance in asthma care. Allergo Int. 2019;68(2):158–66.doi: 10.1016/j.alit.2019.01.004.
  5. Murano A, Lemanaske RF Jr, Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis –PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma &Immunology. J Allergy Clin Immunol. 2016;137 (5): 1347-1358. doi: 10.1016/j.jaci.2016.03.010
  6. Akids M, Aab A, Altunbulakii C. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allegy Clin Immunol. 2016; 138 (4): 984-1010. doi: 10.1016/j.jaci.2016.06.033
  7. Sugita K, Steer CA, M. Martinez-Conzalezet al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J Allergy Clin Immunol. 2018;141 (1):300-310. doi: 10.1016/j.jaci.2017.02.038
  8. Sugita K, Altunbulakii C, Morita C et al., Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL-13. Allergy, 2019;74 (12):2534-2537. DOI: doi.org/10.1111/all.13935
  9. Xiong Y, Cui X, Li W, et al., BLT1 signaling in epithelial cells mediates allergic sensitization via promotion of IL-33 production. Allergy. 2019; 74 (3); 495-506. doi: 10.1111/all.13656
  10. Popadopoulos NG, Barnes P, Canonica GW, Gaga M, Heaney L, Menzies–Gow, Kritikos V. The evolving algorithm of biological selection in severe asthma. Allergy.2020;75;1555-1563. doi: 10.1111/all.14256
  11. Akdis CA, Arkwright PD, Bruggen MCh, Busse W et al. Type 2 immunity the skin and lungs Allergy.2020;75;1582-1605. doi: 10.1111/all.14318
  12. Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals Inc. Dupixent (dupilumab) injection: US prescribing information. 2019. http://www.acces sdata.fda.gov. Accessed 23 Nov 2020.
  13. Shirley M. Dupilumab: First Global Approval. Drugs. 2017;77(10):1115–1121. doi: 10.1007/s40265-017-0768-3

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract: 21

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) Russian Journal of Allergy

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies